nach oben

Current Atherosclerosis Reports

Erschienen in:

01.08.2012 | Cardiovascular Disease and Stroke (M Fink and J Safdieh, Section Editors)

Intracerebral Hemorrhage from Cerebral Venous Thrombosis

verfasst von: Jitphapa Pongmoragot, Gustavo Saposnik

Erschienen in: Current Atherosclerosis Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with the incidence of 0.5 % from all strokes. The clinical presentation with cerebral hemorrhage constitutes a diagnostic challenge. Approximately one- third of CVT patients developed intracerebral hemorrhage (ICH). Associated factors include older age, female sex, acute onset (48 h), headache, decreased level of consciousness, seizure, elevated blood pressure and papilledema. MRI and MR venogram is the most recommend diagnostic modality in CVT. Anticoagulation therapy is the most commonly accepted treatment even in patients with ICH related CVT. Mechanical thrombectomy/thrombolysis may be considered in patients with neurological deterioration despite intensive medical treatment. Intracerebral hemorrhage in the context of CVT is usually associated with poorer outcomes compared to CVT without ICH.

Ribes MF. Des recherches faites sur la phlebite. Rev Med Franc Etrang. 1825;3:5–41.

Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791–8.PubMedCrossRef

Bousser MG, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162–70.PubMedCrossRef

Breteau G, Mounier-Vehier F, Godefroy O, Gauvrit JY, Mackowiak-Cordoliani MA, Girot M, et al. Cerebral venous thrombosis 3-year clinical outcome in 55 consecutive patients. J Neurol. 2003;250:29–35.PubMedCrossRef

Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664–70.PubMedCrossRef

de Bruijn SF, de Haan RJ, Stam J. Clinical features and prognostic factors of cerebral venous sinus thrombosis in a prospective series of 59 patients. For The Cerebral Venous Sinus Thrombosis Study Group. J Neurol Neurosurg Psychiatry. 2001;70:105–8.PubMedCrossRef

Haghighi AB, Edgell RC, Cruz-Flores S, Feen E, Piriyawat P, Vora N, et al. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke. 2012;43:262–4.PubMedCrossRef

Ferro JM, Correia M, Pontes C, Baptista MV, Pita F, Cerebral Venous Thrombosis Portuguese Collaborative Study Group (Venoport). Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis. 2001;11:177–82.PubMedCrossRef

•• Saposnik G, Barinagarrementeria F, Brown Jr RD, Bushnell CD, Cucchiara B, Cushman M, American Heart Association StrokeCouncil and the Council on Epidemiology and Prevention, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:1158–92. This is an excellent review of cerebral venous thrombosis including recommendations for the management of cerebral venous thrombosis.PubMedCrossRef

10.

• Kumral E, Polat F, Uzunköprü C, Callı C, Kitiş O. The clinical spectrum of intracerebral hematoma, hemorrhagic infarct, non-hemorrhagic infarct, and non-lesional venous stroke in patients with cerebral sinus-venous thrombosis. Eur J Neurol. 2011. doi:10.1111/j.1468-1331.2011.03562.x. This study demonstrates the clinical characteristics including risk factors and outcomes in cerebral venous thrombosis with intracerebral hemorrhage.

11.

Girot M, Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F, ISCVT Investigators. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke. 2007;38:337–42.PubMedCrossRef

12.

Wasay M, Kojan S, Dai AI, Bobustuc G, Sheikh Z. Headache in cerebral venous thrombosis: incidence, pattern and location in 200 consecutive patients. J Headache Pain. 2010;11:137–9.PubMedCrossRef

13.

Benabu Y, Mark L, Daniel S, Glikstein R. Cerebral venous thrombosis presenting with subarachnoid hemorrhage. Case report and review. Am J Emerg Med. 2009;27:96–106.PubMedCrossRef

14.

Oda S, Shimoda M, Hoshikawa K, Osada T, Yoshiyama M, Matsumae M. Cortical subarachnoid hemorrhage caused by cerebral venous thrombosis. Neurol Med Chir (Tokyo). 2011;51:30–6.CrossRef

15.

Kato Y, Takeda H, Furuya D, Nagoya H, Deguchi I, Fukuoka T, et al. Subarachnoid hemorrhage as the initial presentation of cerebral venous thrombosis. Intern Med. 2010;49:467–70.PubMedCrossRef

16.

Panda S, Prashantha DK, Shankar SR, Nagaraja D. Localized convexity subarachnoid haemorrhage a sign of early cerebral venous sinus thrombosis. Eur J Neurol. 2010;17:1249–58.PubMedCrossRef

17.

Erbaş G, Oner AY, Akpek S, Tokgoz N. Corpus callosum hematoma secondary to isolated inferior sagittal sinus thrombosis. Acta Radiol. 2006;47:1085–8.PubMedCrossRef

18.

Takahashi S, Shinoda J, Hayashi T. Cerebral venous sinus thrombosis in an adult patient presenting as headache and acute subdural hematoma. J Stroke Cerebrovasc Dis. 2010 Dec 23. [Epub ahead of print].

19.

Singh S, Kumar S, Joseph M, Gnanamuthu C, Alexander M. Cerebral venous sinus thrombosis presenting as subdural haematoma. Australas Radiol. 2005;49:101–3.PubMedCrossRef

20.

Chu K, Kang DW, Kim DE, Roh JK. Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy. J Neurol Sci. 2001;15:27–30.CrossRef

21.

Matsuda M, Matsuda I, Sato M, Handa J. Superior sagittal sinus thrombosis followed by subdural hematoma. Surg Neurol. 1982;18:206–11.PubMedCrossRef

22.

Linn J, Ertl-Wagner B, Seelos KC, Strupp M, Reiser M, Brückmann H, et al. Diagnostic value of multidetector-row CT angiography in the evaluation of thrombosis of the cerebral venous sinuses. AJNR Am J Neuroradiol. 2007;28:946–52.PubMed

23.

Wasay M, Azeemuddin M. Neuroimaging of cerebral venous thrombosis. J Neuroimaging. 2005;15:118–28.PubMed

24.

•• Einhäupl K, Stam J, Bousser MG, De Bruijn SF, Ferro JM, Martinelli I, European Federation of Neurological Societies, et al. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. EurJ Neurol. 2010;17:1229–35. This provides excellent recommendations for the management of cerebral venous thrombosis.CrossRef

25.

Sheerin F. The imaging of the cerebral venous sinuses. Semin Ultrasound CT MR. 2009;30:525–58.PubMedCrossRef

26.

Ganeshan D, Narlawar R, McCann C, Jones HL, Curtis J. Cerebral venous thrombosis-A pictorial review. Eur J Radiol. 2010;74:110–6.PubMedCrossRef

27.

Einhäupl KM, Villringer A, Meister W, Mehraein S, Garner C, Pellkofer M, et al. Heparin treatment in sinus venous thrombosis. Lancet. 1991;338:597–600.PubMedCrossRef

28.

de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30:484–8.PubMedCrossRef

29.

Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev. 2011;(8):CD002005.

30.

Frey JL, Muro GJ, McDougall CG, Dean BL, Jahnke HK. Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin. Stroke. 1999;30:489–94.PubMedCrossRef

31.

Kirsch J, Rasmussen PA, Masaryk TJ, Perl 2nd J, Fiorella D. Adjunctive rheolytic thrombectomy for central venous sinus thrombosis: technical case report. Neurosurgery. 2007;60:577–8.CrossRef

32.

Modi K, Misra V, Reddy P. Rheolytic thrombectomy for dural venous sinus thrombosis. J Neuroimaging. 2009;19:366–9.PubMedCrossRef

33.

Velat GJ, Skowlund CJ, Waters MF, Mocco J, Hoh BL. Direct thrombectomy using the penumbra thromboaspiration catheter for the treatment of cerebral venous sinus thrombosis. World Neurosurg. 2011 Nov 7.

34.

Stam J, Majoie CB, van Delden OM, van Lienden KP, Reekers JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke. 2008;39:1487–90.PubMedCrossRef

35.

Ferro JM, Correia M, Rosas MJ, Pinto AN, Neves G, Cerebral Venous Thrombosis Portuguese Collaborative Study Group[Venoport]. Seizures in cerebral vein and dural sinus thrombosis. Cerebrovasc Dis. 2003;15:78–83.PubMedCrossRef

36.

•• Lansberg MG, O’Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, American College of Chest Physicians, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e601S–36S. This provides excellent recommendations for the management of cerebral venous thrombosis.PubMedCrossRef

Titel: Intracerebral Hemorrhage from Cerebral Venous Thrombosis
verfasst von: Jitphapa Pongmoragot
Gustavo Saposnik
Publikationsdatum: 01.08.2012
Verlag: Current Science Inc.
Erschienen in: Current Atherosclerosis Reports / Ausgabe 4/2012
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-012-0260-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Management of Ruptured Brain Arteriovenous Malformations

Anticoagulation-Related Intracranial Hemorrhages

The Enigma of Genetics Etiology of Atherosclerosis in the Post-GWAS Era

The Pathophysiology and Clinical Presentation of Cerebral Amyloid Angiopathy

Etiologies of Intracerebral Hematomas